NCT03577587 is a NA clinical trial of Silitidil for 21 days in Breast Milk Production, sponsored by Waldkrankenhaus Protestant Hospital, Spandau.

Who is sponsoring NCT03577587?

NCT03577587 is sponsored by Waldkrankenhaus Protestant Hospital, Spandau.

What drugs are being tested in NCT03577587?

Interventions in NCT03577587: Silitidil for 21 days, Placebo for 21 days.

What condition does NCT03577587 study?

NCT03577587 studies Breast Milk Production, Human Milk Feeding, Hypogalactia, Preterm Infant Nutrition.

Is NCT03577587 still recruiting?

NCT03577587 is currently completed. Last updated 3 May 2022.

Last reviewed 2022-05-03 · How we verify

NCT03577587

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Herbal Galactagogue Silitidil After Preterm Birth

Completed NA Last updated 3 May 2022

What this trial tests

NA trial testing Silitidil for 21 days in Breast Milk Production in 106 participants. Completed in 10 February 2022.

Timeline

14 August 2017

Primary endpoint
10 February 2022

10 February 2022

Quick facts

Lead sponsor	Waldkrankenhaus Protestant Hospital, Spandau
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	106
Start date	14 August 2017
Primary completion	10 February 2022
Estimated completion	10 February 2022
Sites	1 location across Germany

Drugs / interventions tested

Silitidil for 21 days
Placebo for 21 days

Conditions studied

Breast Milk Production — all drugs for Breast Milk Production →
Human Milk Feeding — all drugs for Human Milk Feeding →
Hypogalactia — all drugs for Hypogalactia →
Preterm Infant Nutrition — all drugs for Preterm Infant Nutrition →

Sponsor

Waldkrankenhaus Protestant Hospital, Spandau

Who can join

Eligibility, female only, with Breast Milk Production or Human Milk Feeding. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After preterm birth mothers often suffer from hypogalactia. Herbal galactogogues can be used in order to increase milk production. In this double-blind, randomized, placebo-controlled clinical trial the effect of Silitidil, an extract from milk thistle, on the postpartal milk production in mothers of very premature newborns is investigated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03577587 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Waldkrankenhaus Protestant Hospital, Spandau
Last refreshed: 3 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03577587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing